-

Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare.

Natera was ranked among 349 companies across 20 fields of work on factors contributing to job seekers’ decision-making when choosing a workplace that best meets their needs in their industries of interest. In healthcare specifically, Natera earned a spot on the industry list alongside companies across different elements of healthcare operations and services, including biotechnology, life sciences, pharmaceuticals, and hospital operations.

“At Natera, we are committed to fostering a positive workplace environment where employees can learn from one another, further develop in their careers, and continue to thrive – all while contributing to our very important mission,” said Steve Chapman, chief executive officer of Natera. “Natera is a great place to work because of our extremely talented employees, and we are proud to earn a spot on this list alongside so many esteemed companies across different dimensions of healthcare.”

This new recognition by U.S. News expands on the general 2023-2024 U.S. News Best Companies to Work For list by looking at how companies measure up to the expectations of their employees within their respective industries. The rankings take into account quality of pay, work-life balance, and opportunities for professional development and advancement by industry.

To calculate the U.S. News Best Companies to Work For by Industry lists, U.S. News only considered companies that were a part of the Russell 3000 index as of June 2023 and scored in the top 20% of their industry. Additionally, U.S. News required each company to have a minimum of 75 Glassdoor reviews written between 2020-2022 and grouped companies according to the Industry Classification Benchmark (ICB) used by the FTSE Russell.

To learn more about career opportunities at Natera and the core values that define company culture, please visit: www.natera.com/company/careers/.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Natera, Inc.

NASDAQ:NTRA

Release Versions

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal cancer (CRC). The peer-reviewed publication builds upon data that was previously presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The study analyzed 1,230 timepoints from 195 CRC pa...

Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026. EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera’s proprietary, ultra-sensitive LinkedSNP™ technology, Fetal Focus assesses whether a fetus has inherited disease-causing varian...

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digital pathology imaging and tumor sequencing data, to enhance the Signatera™ MRD assessment. Signatera has transformed can...
Back to Newsroom